Education
About Us
Working with TipRanks
Follow Us
Wuxi Biologics (Cayman) (HK:2269)
:2269
RESEARCH TOOLSreports
Total Valuation
Wuxi Biologics (Cayman) has a market cap or net worth of HK$75.08B. The enterprise value is HK$69.84B.
Market CapHK$75.08B
Enterprise ValueHK$69.84B
Share Statistics
Wuxi Biologics (Cayman) has 4.11B shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4.11B
Owened by Insiders
Owened by Instutions0.02%
Financial Efficiency
Wuxi Biologics (Cayman)’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per EmployeeHK$1,700,797.416
Profits Per EmployeeHK$299,441.074
Employee Count12,575
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Wuxi Biologics (Cayman) is ―. Wuxi Biologics (Cayman)’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Wuxi Biologics (Cayman) had revenue of HK$21.39B and earned HK$3.77B in profits. Earnings per share was HK$0.73.
RevenueHK$21.39B
Gross ProfitHK$8.25B
Operating IncomeHK$4.28B
Pretax IncomeHK$4.48B
Net IncomeHK$3.77B
EBITDA5.60B
Earnings Per Share (EPS)0.73
Cash Flow
In the last 12 months, operating cash flow was HK$3.64B and capital expenditures -HK$3.98B, giving a free cash flow of -HK$346.67M billion.
Operating Cash FlowHK$3.64B
Free Cash Flow-HK$346.67M
Free Cash Flow per Share-HK$0.08
Dividends & Yields
Wuxi Biologics (Cayman) pays an annual dividend of HK$0.05, resulting in a dividend yield of
Dividend Per ShareHK$0.05
Dividend Yield
Payout Ratio
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.72
52-Week Price Change24.27%
50-Day Moving Average23.38
200-Day Moving Average16.59
Relative Strength Index (RSI)59.03
Average Volume (3m)67.36M
Important Dates
Wuxi Biologics (Cayman) upcoming earnings date is Aug 25, 2025, Before Open.
Last Earnings DateMar 25, 2025
Next Earnings DateAug 25, 2025
Ex-Dividend DateNov 2, 2023
Financial Position
Wuxi Biologics (Cayman) as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Wuxi Biologics (Cayman) has paid HK$846.16M in taxes.
Income TaxHK$846.16M
Effective Tax Rate―
Enterprise Valuation
Wuxi Biologics (Cayman) EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Wuxi Biologics (Cayman) has HK$9.53B in cash and marketable securities with HK$4.57B in debt, giving a net cash position of -HK$4.96B billion.
Cash & Marketable SecuritiesHK$9.53B
Total DebtHK$4.57B
Net Cash-HK$4.96B
Net Cash Per Share-HK$1.21
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Wuxi Biologics (Cayman) is HK$31.51, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$31.51
Price Target Upside76.82%
Analyst ConsensusModerate Buy
Analyst Count10
Revenue Growth Forecast
EPS Growth Forecast